Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 19 articles: HTML format

Single Articles

June 2026
1. ROELS J, Ghaedi H, Kancherla J, Yang Y, et al
   The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti-PD-L1-Resistant Cancer.
   Cancer Res. 2026;86:2592-2605.
   PubMed     Abstract available
   
   
   February 2026
2. LUO W, Wang Y, Wang H, Ji YA, et al
   CCL5hi-CD4+ T cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer.
   Cancer Res. 2026 Feb 18. doi: 10.1158/0008-5472.CAN-25-2220.
   PubMed     Abstract available
   
   
   October 2025
3. WU J, Cheng B, Song Y, Cheng J, et al
   Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer.
   Cancer Res. 2025 Oct 9. doi: 10.1158/0008-5472.CAN-25-0024.
   PubMed     Abstract available
   
   
   August 2025
4. CHEN C, Gao Y, Lu R, Wu Y, et al
   TERC Stimulates Fatty Acid Metabolism to Promote Bladder Cancer Progression.
   Cancer Res. 2025 Aug 4. doi: 10.1158/0008-5472.CAN-24-3439.
   PubMed     Abstract available
   
   
   March 2025
5. YU Y, Gao X, Zhao H, Sun J, et al
   A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer.
   Cancer Res. 2025 Mar 24. doi: 10.1158/0008-5472.CAN-24-3217.
   PubMed     Abstract available
   
   
   December 2024
6. PRABAGAR MG, McQueney M, Bommireddy V, Siegel R, et al
   THE STING AGONIST VB-85247 INDUCES DURABLE ANTITUMOR IMMUNE RESPONSES BY INTRAVESICAL ADMINISTRATION IN A NON-MUSCLE INVASIVE BLADDER CANCER.
   Cancer Res. 2024 Dec 19. doi: 10.1158/0008-5472.CAN-24-1022.
   PubMed     Abstract available
   
   
   September 2024
7. CUI C, Zhang H, Yang C, Yin M, et al
   Inhibition of JNK Signaling Overcomes Cancer-Associated Fibroblast-Mediated Immunosuppression and Enhances the Efficacy of Immunotherapy in Bladder Cancer.
   Cancer Res. 2024 Sep 18. doi: 10.1158/0008-5472.CAN-24-0940.
   PubMed     Abstract available
   
   
   August 2024
8. KELLER PJ, Adams EJ, Wu R, Cote A, et al
   Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.
   Cancer Res. 2024;84:2501-2517.
   PubMed     Abstract available
   
   
   July 2024
9. ZENG Y, Luo Y, Zhao K, Liu S, et al
   m6A-Mediated Induction of 7-Dehydrocholesterol Reductase Stimulates Cholesterol Synthesis and cAMP Signaling to Promote Bladder Cancer Metastasis.
   Cancer Res. 2024 Jul 24. doi: 10.1158/0008-5472.CAN-23-3703.
   PubMed     Abstract available
   
   
   
10. YANG Y, Suhasini AN, Jiang Z, Liu N, et al
    A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants.
    Cancer Res. 2024;84:2169-2180.
    PubMed     Abstract available
    
    
    May 2024
11. JONES RT, Scholtes M, Goodspeed A, Akbarzadeh M, et al
    NPEPPS Is a Druggable Driver of Platinum Resistance.
    Cancer Res. 2024;84:1699-1718.
    PubMed     Abstract available
    
    
    March 2024
12. HOSNI S, Kilian V, Klumper N, Gabbia D, et al
    Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
    Cancer Res. 2024;84:725-740.
    PubMed     Abstract available
    
    
    November 2023
13. ZHAO Y, Chen J, Zheng H, Luo Y, et al
    SUMOylation-driven mRNA circularization enhances translation and promotes lymphatic metastasis of bladder cancer.
    Cancer Res. 2023 Nov 22. doi: 10.1158/0008-5472.CAN-23-2278.
    PubMed     Abstract available
    
    
    October 2023
14. GARCIA-RODRIGUEZ JL, Korsgaard U, Ahmadov U, Jarlstad Olesen MT, et al
    Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells.
    Cancer Res. 2023;83:3340-3353.
    PubMed     Abstract available
    
    
    September 2023
15. OUYANG Y, Ou Z, Zhong W, Yang J, et al
    FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation.
    Cancer Res. 2023 Sep 28. doi: 10.1158/0008-5472.CAN-23-1065.
    PubMed     Abstract available
    
    
    April 2023
16. OWCZAREK TB, Kobayashi T, Ramirez R, Rong L, et al
    Correction: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
    Cancer Res. 2023;83:1159.
    PubMed    
    
    
    March 2023
17. ZHUANG J, Shen L, Li M, Sun J, et al
    Cancer-associated fibroblast-derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance.
    Cancer Res. 2023 Mar 20:CAN-22-2213. doi: 10.1158/0008-5472.CAN-22-2213.
    PubMed     Abstract available
    
    
    
18. ZHANG L, Li Y, Zhou L, Zhou H, et al
    The m6A reader YTHDF2 promotes bladder cancer progression by suppressing RIG-I-mediated immune response.
    Cancer Res. 2023 Mar 20:CAN-22-2485. doi: 10.1158/0008-5472.CAN-22-2485.
    PubMed     Abstract available
    
    
    
19. XIE R, Cheng L, Huang M, Huang L, et al
    NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer.
    Cancer Res. 2023 Mar 20:CAN-22-2233. doi: 10.1158/0008-5472.CAN-22-2233.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum